Because of its close relationship with type 2 diabetes and Alzheimer’s disease, IDE has attracted much attention as a target for new drug development, but the mechanism of its binding with different targets has not been clear. This evidence concerns the gene IDE and early-onset autosomal dominant Alzheimer disease.